Pulling SEC filings + quote and writing the call…

WEX Inc.
Next earnings Jul 21, 2026 (before open) · consensus $5.10 EPS, $746M rev
Last earnings +4.2% on 2026-04-22
Cheap cash-gusher buying back ~16% of float a year at 15.9x earnings — the leverage optics overstate the real risk.
P/E (trailing) 15.9 · FY2025
The fundamentals carry the rating, but the price is rich (~51% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
WEX is a high-margin, cash-generative payments-and-benefits franchise trading at just 15.9x trailing diluted EPS and 2.5x sales, despite a 36.0% operating margin, 16.5% net margin and a 24.6% ROE. FY2025 revenue slipped 1.2% to $1.85B and net income eased 1.8% to $304M, but diluted EPS still grew 12.9% to $8.47 because the company hammered share count down 11.6% via $750M of buybacks (up 15.0% YoY). That is the entire setup: a slow-growth, durably profitable business returning enormous amounts of capital, with the per-share line meaningfully outrunning the absolute P&L.
The scary-looking 10.66x liabilities/equity ratio is mostly a feature of WEX Bank's industrial-bank balance sheet, not corporate leverage. The MD&A confirms the credit-agreement covenant tests a 'consolidated leverage ratio of less than 3.50:1.00' that explicitly excludes up to $400M of permitted securitizations, the non-recourse portion of factoring, and up to $500M of unrestricted cash — i.e. the headline liabilities figure is not what the lenders price. Long-term debt of $3.53B against $664M operating income and $906M cash (up 52% YoY) is workable, and $454M of operating cash flow comfortably covers $141M of capex. Retained earnings rose 14.7% to $2.37B even after the buyback — equity only shrank because management is aggressively retiring stock, which is the right move at this multiple.
Is WEX a buy? The one-page verdict, explained →
High-conviction BUY: a wider spread keeps more of the upside while the short call still cuts cost and decay.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.35B | $1.69B | $1.84B | $1.87B | $1.85B |
| Gross profit | — | — | — | — | — |
| Operating income | $342M | $470M | $647M | $686M | $664M |
| Net income | $135M | $167M | $267M | $310M | $304M |
| Diluted EPS | $0.00 | $4.50 | $6.16 | $7.50 | $8.47 |
| Net margin | 10.1% | 9.9% | 14.5% | 16.6% | 16.5% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results disclosed; routine governance update for shareholders.
Entered material agreement (Item 1.01) with Reg FD disclosure; terms shape capital structure.
Q1 2026 10-Q filed; quarterly financials and MD&A for the period ended 2026-03-31.
Q1 2026 earnings release furnished; results drive +3% move and frame full-year outlook.
FY25: rev -1.2%, NI -1.8%, but $750M buyback (-11.6% shares) lifted diluted EPS +12.9%.
Q4/FY25 earnings: rev -1.2% but diluted EPS +12.9% on $750M buyback shrinking float.
Officer/director change announced (Item 5.02); leadership transition signal for holders.
Q3 2025 10-Q filed; interim results and risk/MD&A disclosure for the quarter.
Q3 2025 earnings paired with officer change; mixed signal on execution continuity.
Sources: SEC EDGAR (CIK 0001309108, latest 10-Q filed 2026-04-23) · EODHD · Proprietary analysis · as of 6/25/2026, 12:46:52 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 8:46 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 1 open-market buy · 1 sale
| 2026-06-30 | Wolfe Lauren Taylor Director | Award | 79.00 | |
| 2026-06-30 | GROCH JAMES R Director | Award | 186.00 | |
| 2026-06-30 | Callahan Don Director | Award | 186.00 | |
| 2026-06-30 | Adams Kurt Patrick Director | Award | 79.00 | |
| 2026-06-17 | Trickett Sara Chief Legal Officer | Exercise | 98.00 | |
| 2026-06-17 | Trickett Sara Chief Legal Officer | Tax | 29.00 @ $131.27 | $3.81K |
| 2026-06-17 | Trickett Sara Chief Legal Officer | Exercise | 75.00 | |
| 2026-06-17 | Trickett Sara Chief Legal Officer | Tax | 23.00 @ $131.27 | $3.02K |
| 2026-06-17 | Carriedo Carlos COO, Amer. Payments & Mobility | Exercise | 391.00 | |
| 2026-06-17 | Carriedo Carlos COO, Amer. Payments & Mobility | Tax | 174.00 @ $131.27 | $22.8K |
| 2026-05-28 | Deshaies Robert Joseph COO, Benefits | Sell | 1.20K @ $144.84 | $174K |
| 2026-05-18 | GROCH JAMES R Director | Buy | 1.50K @ $142.95 | $214K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1194 tracked peers · median